Thalia Therapeutics Wraps Up In Vitro Study for Lipisiran Cardiovascular Program

MT Newswires · 2d ago
05:58 AM EST, 11/11/2026 (MT Newswires) -- Thalia Therapeutics (THAT.L) completed an in vitro study for its green silencing cardiovascular risk reduction program, Lipisiran. The British clinical-stage biotechnology company said Wednesday that the study achieved target goals, allowing the program to move to in vivo studies to determine efficacy and durability. Lipisiran is a dual-acting small interfering RNA therapeutic candidate designed to target PCSK9 and lipoprotein(a) to lower the risk of heart attacks and strokes.